Citigroup
GEVA

Citigroup’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Citigroup’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-24,725
Closed -$2.41M – 8066
2015
Q1 		$2.41M Buy
24,725
+11,246
+83% +$1.19M ﹤0.01% 2316
2014
Q4 		$1.25M Buy
13,479
+10,906
+424% +$861K ﹤0.01% 2909
2014
Q3 		$177K Buy
2,573
+377
+17% +$27K ﹤0.01% 4323
2014
Q2 		$230K Sell
2,196
-4,760
-68% -$405K ﹤0.01% 4031
2014
Q1 		$577K Sell
6,956
-1,210
-15% -$112K ﹤0.01% 3330
2013
Q4 		$529K Buy
8,166
+2,773
+51% +$165K ﹤0.01% 3745
2013
Q3 		$341K Buy
5,393
+4,838
+872% +$238K ﹤0.01% 3749
2013
Q2 		$24K Buy
+555
New +$25.3K ﹤0.01% 5752

Citigroup's GEVA Position: Q2 2015 in Review

Citigroup sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 24,725 shares — an estimated $2.41M sold.

Citigroup first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.41M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Citigroup reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Citigroup sold 24,725 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $2.41M.
  • Citigroup first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Citigroup's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.41M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Citigroup's 13F filing for Q2 2015, filed 13 Aug 2015.